BL
BLTE
BELITE BIO, INC
$138.16
+0.96%
$5.4B
No data for this timeframe.
Vol
Market Cap$5.4B
Cap SizeMid Cap
Analyst ConsensusStrong Buy (93%)
Inst. Holders31 funds
Inst. Value$282.3M
Inst. Activity4 buys / 4 sells
Insider Activity0B / 19S
Insider Net $-$1.3M
SEC Reports5
Press Releases1
Recent Activity
Jun 13, 2026
fda
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
<p align="left">SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.co
May 20, 2026
SEC
Belite Bio reported Q1 2026 GAAP EPS of -$0.68, missing the -$0.64 consensus by 6.3%, with net loss widening to $26.9M f
PRESS-RELEASE — Impact 6/10
May 7, 2026
Insider
MATA NATHAN L. sold 226 shares
Chief Scientific Officer @ $152.45 ($34.5K)
May 6, 2026
Insider
MATA NATHAN L. sold 8 shares
Chief Scientific Officer @ $151.57 ($1.2K)
May 5, 2026
Insider
MATA NATHAN L. sold 120 shares
Chief Scientific Officer @ $153.92 ($18.5K)
Apr 21, 2026
SEC
Belite Bio announced the initiation of a rolling NDA submission to the FDA for tinlarebant, a potential treatment for St
PRESS-RELEASE — Impact 5/10
Apr 21, 2026
SEC
Belite Bio announced the initiation of a rolling submission of a New Drug Application (NDA) to the FDA for tinlarebant,
6-K — Impact 8/10
Inst.
Holocene Advisors, LP — DOUBLED
494,495 shares ($78.8M)
Price Targets
$210.50
+52.4% upside
Strong Buy
Current $138.16
Low $185.00
Median $200.50
High $266.00
8 analysts
$185.00
$266.00
Analyst Ratings
4Strong Buy
9Buy
1Hold
0Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| May 26, 2026 | Mizuho | MAINTAIN | Outperform → Outperform |
| May 21, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 22, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Apr 13, 2026 | HC Wainwright & Co. | REITERATE | Buy → Buy |
| Mar 3, 2026 | HC Wainwright & Co. | MAINTAIN | Buy → Buy |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.77 ▼ -15.4% | $-0.99 — $-0.54 | -55% YoY | 7 |
| Next Q | $-0.82 ▼ -19.2% | $-1.17 — $-0.53 | -26% YoY | 7 |
| Current FY | $-3.28 ▼ -54.2% | $-4.28 — $-2.77 | -42% YoY | 7 |
| Next FY | $0.94 ▲ +20.3% | $-4.43 — $8.83 | 129% YoY | 7 |
Latest Reports
MIXED
PRESS-RELEASE
6/10
Belite Bio reported Q1 2026 GAAP EPS of -$0.68, missing the -$0.64 consensus by 6.3%, with net loss widening to $26.9M f
May 20, 2026
NEUTRAL
PRESS-RELEASE
5/10
Belite Bio announced the initiation of a rolling NDA submission to the FDA for tinlarebant, a potential treatment for St
Apr 21, 2026
BULLISH
Press
9/10
Belite Bio reported preliminary 2025 financial results and provided a significant business update, including positive Ph
Mar 2, 2026
Top Institutional Holders
| Fund | Value | Move |
|---|---|---|
| RTW INVESTMENTS, LP | $114.1M | DOUBLED |
| Holocene Advisors, LP | $78.8M | DOUBLED |
| MORGAN STANLEY | $32.1M | DOUBLED |
| GOLDMAN SACHS GROUP INC | $16.8M | — |
| FRED ALGER MANAGEMENT, LLC | $10.0M | NEW |
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| May 7, 2026 | MATA NATHAN | SELL | $34.5K |
| May 6, 2026 | MATA NATHAN | SELL | $1.2K |
| May 5, 2026 | MATA NATHAN | SELL | $18.5K |
| May 4, 2026 | MATA NATHAN | SELL | $4.9K |
| May 1, 2026 | MATA NATHAN | SELL | $8.0K |
31 institutional holders with $282.3M total value (2,169,292 shares) as of 2026-Q1. Top holders: RTW, Holocene, MORGAN.
Top Institutional Holders — 2026-Q1
| # | Fund | Shares | Value | % of Tracked | Last Move |
|---|---|---|---|---|---|
| 1 | RTW INVESTMENTS, LP | 715,332 | $114.1M | 40.4% | DOUBLED +128.9% |
| 2 | Holocene Advisors, LP | 494,495 | $78.8M | 27.9% | DOUBLED +488.2% |
| 3 | MORGAN STANLEY | 201,409 | $32.1M | 11.4% | DOUBLED +619.0% |
| 4 | GOLDMAN SACHS GROUP INC | 105,509 | $16.8M | 6.0% | — |
| 5 | FRED ALGER MANAGEMENT, LLC | 62,574 | $10.0M | 3.5% | NEW |
| 6 | RENAISSANCE TECHNOLOGIES LLC | 52,000 | $8.3M | 2.9% | TRIM -34.6% |
| 7 | TD ASSET MANAGEMENT INC | 33,410 | $5.3M | 1.9% | — |
| 8 | MANUFACTURERS LIFE INSURANCE COMPANY, THE | 19,600 | $3.1M | 1.1% | — |
| 9 | STATE STREET CORP | 16,048 | $2.6M | 0.9% | TRIM -34.3% |
| 10 | BANK OF MONTREAL /CAN/ | 15,981 | $2.5M | 0.9% | — |
| 11 | Trexquant Investment LP | 15,072 | $2.4M | 0.9% | — |
| 12 | Blackstone Inc. | 10,692 | $1.7M | 0.6% | — |
| 13 | BARCLAYS PLC | 6,822 | $1.1M | 0.4% | — |
| 14 | Amundi | 4,210 | $671.2K | 0.2% | — |
| 15 | BANK OF AMERICA CORP /DE/ | 3,778 | $602.4K | 0.2% | DOUBLED +104.0% |
| 16 | AMERIPRISE FINANCIAL INC | 2,767 | $441.2K | 0.2% | NEAR_EXIT -79.1% |
| 17 | ROYAL BANK OF CANADA | 2,257 | $360.0K | 0.1% | — |
| 18 | CITADEL ADVISORS LLC | 2,008 | $320.2K | 0.1% | ADD +45.2% |
| 19 | TUDOR INVESTMENT CORP ET AL | 1,596 | $254.5K | 0.1% | — |
| 20 | Merit Financial Group, LLC | 1,415 | $225.6K | 0.1% | — |
Recent Position Changes
| Fund | Action | Prev Shares | Curr Shares | Change % | Value | Quarter |
|---|---|---|---|---|---|---|
| Holocene Advisors, LP | DOUBLED | 84,067 | 494,495 | +488.2% | $78.8M | 2026-Q1 |
| MORGAN STANLEY | DOUBLED | 28,013 | 201,409 | +619.0% | $32.1M | 2026-Q1 |
| BANK OF AMERICA CORP /DE/ | DOUBLED | 1,852 | 3,778 | +104.0% | $602.4K | 2026-Q1 |
| AMERIPRISE FINANCIAL INC | NEAR_EXIT | 13,221 | 2,767 | -79.1% | $441.2K | 2026-Q1 |
| HRT FINANCIAL LP | ADD | 8,164 | 10,922 | +33.8% | $1.7K | 2026-Q1 |
| RA CAPITAL MANAGEMENT, L.P. | EXIT | 432,484 | 0 | -100.0% | $0.00 | 2026-Q1 |
| Point72 Asset Management, L.P. | EXIT | 284,437 | 0 | -100.0% | $0.00 | 2026-Q1 |
| MARSHALL WACE, LLP | EXIT | 192,700 | 0 | -100.0% | $0.00 | 2026-Q1 |
| RTW INVESTMENTS, LP | DOUBLED | 312,500 | 715,332 | +128.9% | $114.4M | 2025-Q4 |
| RA CAPITAL MANAGEMENT, L.P. | TRIM | 875,000 | 432,484 | -50.6% | $69.2M | 2025-Q4 |
| Point72 Asset Management, L.P. | DOUBLED | 3,100 | 284,437 | +9075.4% | $45.5M | 2025-Q4 |
| Holocene Advisors, LP | NEW | — | 84,067 | — | $13.4M | 2025-Q4 |
| FRED ALGER MANAGEMENT, LLC | NEW | — | 79,394 | — | $12.7M | 2025-Q4 |
| MORGAN STANLEY | DOUBLED | 5,230 | 28,013 | +435.6% | $4.5M | 2025-Q4 |
| AMERIPRISE FINANCIAL INC | DOUBLED | 3,031 | 13,221 | +336.2% | $2.1M | 2025-Q4 |
| BANK OF AMERICA CORP /DE/ | ADD | 1,171 | 1,852 | +58.2% | $296.2K | 2025-Q4 |
| RA CAPITAL MANAGEMENT, L.P. | NEW | — | 875,000 | — | $64.8M | 2025-Q3 |
| RTW INVESTMENTS, LP | NEW | — | 312,500 | — | $23.1M | 2025-Q3 |
| MARSHALL WACE, LLP | DOUBLED | 9,486 | 187,500 | +1876.6% | $13.9M | 2025-Q3 |
| STATE STREET CORP | TRIM | 20,203 | 13,273 | -34.3% | $982.2K | 2025-Q3 |
| UBS Group AG | DOUBLED | 2,358 | 11,334 | +380.7% | $838.7K | 2025-Q3 |
| CITADEL ADVISORS LLC | ADD | 7,456 | 10,827 | +45.2% | $801.2K | 2025-Q3 |
| MORGAN STANLEY | DOUBLED | 507 | 5,230 | +931.6% | $387.0K | 2025-Q3 |
| Point72 Asset Management, L.P. | DOUBLED | 1,300 | 3,100 | +138.5% | $229.4K | 2025-Q3 |
| RENAISSANCE TECHNOLOGIES LLC | TRIM | 4,300 | 2,812 | -34.6% | $208.1K | 2025-Q3 |
5 unique insiders with 26 transactions. Net insider value: -$1.3M ($0.00 bought, $1.3M sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| May 7, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 226 | $152.45 | $34.5K |
| May 6, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 8 | $151.57 | $1.2K |
| May 5, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 120 | $153.92 | $18.5K |
| May 4, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 32 | $153.50 | $4.9K |
| May 1, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 52 | $153.89 | $8.0K |
| Apr 29, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 278 | $154.58 | $43.0K |
| Apr 28, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 12 | $154.65 | $1.9K |
| Apr 27, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 44 | $160.83 | $7.1K |
| Apr 24, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 74 | $157.86 | $11.7K |
| Apr 23, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 267 | $164.47 | $43.9K |
| Apr 22, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 31 | $165.70 | $5.1K |
| Apr 21, 2026 | Scholl Hendrik Peter | Chief Medical Officer | J | 10,000 | — | — |
| Apr 21, 2026 | Chuang Hao-Yuan | Chief Financial Officer | J | 10,000 | — | — |
| Apr 21, 2026 | Lin Yu-Hsin | Chief Executive Officer | J | 10,000 | — | — |
| Apr 21, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 64 | $163.49 | $10.5K |
| Apr 20, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 284 | $162.76 | $46.2K |
| Apr 17, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 32 | $158.46 | $5.1K |
| Apr 16, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 216 | $158.28 | $34.2K |
| Apr 15, 2026 | MATA NATHAN L. | Chief Scientific Officer | SELL | 383 | $167.58 | $64.2K |
| Apr 9, 2026 | Lin Yu-Hsin | Chief Executive Officer | SELL | 2,500 | $180.36 | $450.9K |
| Apr 9, 2026 | Chen Wan-Shan | Director | SELL | 1,100 | $180.43 | $198.5K |
| Apr 9, 2026 | Chuang Hao-Yuan | Chief Financial Officer | SELL | 2,000 | $180.35 | $360.7K |
| Mar 31, 2026 | MATA NATHAN L. | Chief Scientific Officer | AWARD | 144,868 | — | — |
| Mar 31, 2026 | Chuang Hao-Yuan | Chief Financial Officer | AWARD | 144,868 | — | — |
| Mar 31, 2026 | Lin Yu-Hsin | Chief Executive Officer | AWARD | 206,954 | — | — |
| Mar 31, 2026 | Chen Wan-Shan | Director | AWARD | 13,796 | — | — |
5 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 1 mixed, 1 neutral. Avg impact: 6.4/10.
MIXED
PRESS-RELEASE
6/10
Belite Bio reported Q1 2026 GAAP EPS of -$0.68, missing the -$0.64 consensus by 6.3%, with net loss
May 20, 2026
NEUTRAL
PRESS-RELEASE
5/10
Belite Bio announced the initiation of a rolling NDA submission to the FDA for tinlarebant, a potent
Apr 21, 2026
BULLISH
6-K
8/10
Belite Bio announced the initiation of a rolling submission of a New Drug Application (NDA) to the F
Apr 21, 2026
BEARISH
CLUSTER
7/10
Four insiders at Belite Bio, including the CEO, CFO, and Chief Scientific Officer, sold shares in a
Apr 20, 2026
BEARISH
CLUSTER
6/10
Two C-suite executives at Belite Bio sold shares in a coordinated 7-day window, totaling $812K in op
Apr 13, 2026
Current analyst consensus: Strong Buy (93% buy). Based on 14 analysts: 4 strong buy, 9 buy, 1 hold, 0 sell, 0 strong sell.
Analyst Price Targets
$210.50 mean target
+52.4% upside
Strong Buy (3.00)
$185.00 Low
$266.00 High
| Metric | Value |
|---|---|
| Current Price | $138.16 |
| Target Low | $185.00 |
| Target Mean | $210.50 |
| Target Median | $200.50 |
| Target High | $266.00 |
| # Analysts | 8 |
| Recommendation | Strong Buy (3.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.77 | $-0.99 | $-0.54 | -54.6% | -15.4% | 3↑ 4↓ | $0.0B | 0.0% | 7 |
| Next Q 2026-09-30 |
$-0.82 | $-1.17 | $-0.53 | -25.7% | -19.2% | 3↑ 4↓ | $0.0B | 0.0% | 7 |
| Current FY 2026-12-31 |
$-3.28 | $-4.28 | $-2.77 | -42.2% | -54.2% | 2↑ 5↓ | $0.0B | 0.0% | 7 |
| Next FY 2027-12-31 |
$0.94 | $-4.43 | $8.83 | 128.8% | +20.3% | 2↑ 4↓ | $0.2B | 0.0% | 7 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.773 | |
| 7d ago | $-0.670 | -0.103 |
| 30d ago | $-0.670 | -0.103 |
| 60d ago | $-0.670 | -0.103 |
| 90d ago | $-0.544 | -0.229 |
5 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 2 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| May 26, 2026 | Mizuho | MAINTAIN | Outperform | Outperform |
| May 21, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 22, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Apr 13, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Mar 3, 2026 | HC Wainwright & Co. | MAINTAIN | Buy | Buy |
| Mar 3, 2026 | Morgan Stanley | MAINTAIN | Overweight | Overweight |
| Mar 3, 2026 | Cantor Fitzgerald | MAINTAIN | Overweight | Overweight |
| Jan 28, 2026 | HC Wainwright & Co. | REITERATE | Buy | Buy |
| Jan 26, 2026 | B of A Securities | INITIATE | — | Buy |
| Jan 6, 2026 | Morgan Stanley | INITIATE | — | Overweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| May 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Apr 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Mar 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Feb 1, 2026 | 4 | 9 | 1 | 0 | 0 | 93% | |
| Jan 1, 2026 | 3 | 8 | 1 | 0 | 0 | 92% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 13, 2026
fda
Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1
<p align="left">SAN DIEGO, June 12, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=-5s4_KzPcDXS9J2_kOKPTQqRaTu9a_GA3tN
May 20, 2026
earnings
Belite Bio Reports Unaudited First Quarter 2026 Financial Results and Provides a Corporate Update
<p>SAN DIEGO, May 20, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio<sup>®</sup>” or the “Company”), a clinical-stage drug dev
May 18, 2026
other
Belite Bio Receives Orphan Drug Status for Tinlarebant in Stargardt Disease in Switzerland
<p>SAN DIEGO, May 18, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=yvhQFFBX1ImgbAGCocOmUjw2Pf4fMAxBcBYDPT3K1CPmTp8KF
May 13, 2026
earnings
Belite Bio to Host Webcast on May 20, 2026, to Discuss First Quarter 2026 Financial Results
<p>SAN DIEGO, May 13, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=uZCYcf2BJhPFOUp0Axut21S-4Es8vvEMWvMjHfKf2SHyO1FFr
May 11, 2026
earnings_calendar
BLTE Q1 2026 Earnings Scheduled — 2026-05-11
Apr 21, 2026
earnings
Belite Bio Initiates Rolling Submission of New Drug Application to the U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease
<p>SAN DIEGO, April 21, 2026 (GLOBE NEWSWIRE) -- <a href="https://www.globenewswire.com/Tracker?data=mL9FJnYlM-LbSOcpf6P6kFIqzxZh2mYjOlV_NBZkiK2Xlz_
Mar 31, 2026
regulatory
Belite Bio Announces Availability of Annual Report on Form 20-F Through Company Website
<p align="justify">SAN DIEGO, March 31, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE), a clinical-stage development company focused on adv
Mar 5, 2026
short_interest
FTD: BLTE — 4,392 shares ($0.8M) failed to deliver
Settlement: 20260305, Price: $177.79, FTD Value: $780,853.68, BELITE BIO INC ADR (CYM)
Mar 4, 2026
short_interest
FTD: BLTE — 18,703 shares ($3.1M) failed to deliver
Settlement: 20260304, Price: $167.88, FTD Value: $3,139,859.64, BELITE BIO INC ADR (CYM)
Mar 3, 2026
short_interest
FTD: BLTE — 4,099 shares ($0.7M) failed to deliver
Settlement: 20260303, Price: $177.58, FTD Value: $727,900.42, BELITE BIO INC ADR (CYM)
Mar 2, 2026
earnings
Belite Bio Reports Preliminary, Unaudited Fourth Quarter and Full Year 2025 Financial Results and Provides a Corporate Update
<p>SAN DIEGO, March 02, 2026 (GLOBE NEWSWIRE) -- Belite Bio, Inc (NASDAQ: BLTE) (“Belite Bio” or the “Company”), a clinical-stage drug development c
Mar 2, 2026
earnings_calendar
BLTE Q4 2025 Earnings Before Market Open — 2026-03-02